CEO of Bethesda's Northwest Biotherapeutics loans her company $4.4M
Linda Powers, the CEO of Bethesda biotech Northwest Biotherapeutics Inc., is loaning the company $4.4 million, a Securities and Exchange Commission filing shows.
Northwest Bio (OTC: NWBO), which is in the midst of a phase 3 clinical trial for its immunotherapy drug candidate for glioblastoma multiforme brain cancer, earlier this month entered into two separate note and loan agreements with Powers. The two notes, one for $4 million and the other for $400,00 0, will convert into preferred stock at…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Tina Reed Source Type: news
More News: Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Health Management | Immunotherapy | Neurology